

ARTICLE OPEN

NF- κ B regulated expression of A20 controls IKK dependent repression of RIPK1 induced cell death in activated T cellsScott Layzell¹, Alessandro Barbarulo¹, Geert van Loo^{1,2}, Rudi Beyaert^{1,2} and Benedict Seddon¹✉

© The Author(s) 2024, corrected publication 2024

IKK signalling is essential for survival of thymocytes by repressing RIPK1 induced cell death rather than its canonical function of activating NF- κ B. The role of IKK signalling in activated T cells is unclear. To investigate this, we analysed activation of IKK2 deficient T cells. While TCR triggering was normal, proliferation and expansion was profoundly impaired. This was not due to defective cell cycle progression, rather dividing T cells became sensitised to TNF induced cell death, since inhibition of RIPK1 kinase activity rescued cell survival. Gene expression analysis of activated IKK2 deficient T cells revealed defective expression of *Tnfrsf25*, that encodes A20, a negative regulator of NF- κ B. To test whether A20 expression was required to protect IKK2 deficient T cells from cell death, we generated mice with T cells lacking both A20 and IKK2. Doing this resulted in near complete loss of peripheral T cells, in contrast to mice lacking one or other gene. Strikingly, this phenotype was completely reversed by inactivation of RIPK1 kinase activity in vivo. Together, our data show that IKK signalling in activated T cells protects against RIPK1 dependent death, both by direct phosphorylation of RIPK1 and through NF- κ B mediated induction of A20, that we identify for the first time as a key modulator of RIPK1 activity in T cells.

Cell Death & Differentiation (2025) 32:256–270; <https://doi.org/10.1038/s41418-024-01383-6>

INTRODUCTION

The NF- κ B family of transcription factors play critical roles in controlling development and function of many cell types [1]. Canonical NF- κ B signalling is mediated by hetero or homodimers of p50, RELA and cREL family members that are sequestered in the cytoplasm by inhibitory proteins, the Inhibitors of kappa B (I κ B) family and the related protein NFKB1. The key regulator of NF- κ B dimer release is the inhibitor of kappa-B kinase (IKK) complex, a trimeric complex of two kinases, IKK1 (IKK α) and IKK2 (IKK β), and a third regulatory component, NEMO (IKK γ). IKK phosphorylates I κ B proteins, targeting them for degradation by the proteasome and releasing NF- κ B dimers to enter the nucleus. During immune responses by T cells, activation of NF- κ B is a critical early event following T cell receptor antigen recognition (reviewed in [2]). In the absence of REL subunits, or upstream NF- κ B activators, such as TAK1 or IKK complex, T cells fail to blast transform or enter cell cycle [3, 4]. Consequently, mice with T cell specific ablation of RelA and/or cRel have peripheral naive T cells, but lack effector or memory phenotype T cells [4, 5]. Similarly, disruption of the CARD11-BCL10-MALT1 (CBM) complex that links TCR triggering to NF- κ B activation also prevents T cell activation [6–11]. Blast transformation of activated T cells is mediated by induction of c-Myc, and NF- κ B is essential for c-Myc expression in mouse T cells [12, 13].

Because of the critical function in T cell priming, it is less clear how NF- κ B signalling contributes to later stages of T cell activation and effector differentiation. Analysis of upstream regulators of

NF- κ B activation provide some indications. Limited redundancy between IKK1 and IKK2 permits activation of T cells lacking one or other subunit [14, 15]. However, IKK complexes formed by homodimers of either IKK1 or IKK2 are hypomorphic, and mice with T cell specific ablation of individual subunits exhibit reduced effector/memory compartments, most notably in IKK2 deficient mice [14]. Conversely, loss of negative regulators of NF- κ B activation in mouse T cells result in de-repression of NF- κ B activation and corresponding perturbations to T cell compartments. A20 is a potent suppressor of NF- κ B activation. A20 deficient T cells have enhanced NF- κ B activation that promotes anti-tumour CD8⁺ T cell responses [16] and development of intrathymic Treg [17]. In spite of the expanded regulatory T cell pool, de-repression of NF- κ B activation in these mice also results in increased numbers of effector and memory T cells [18]. Several mechanisms have been proposed for how A20 inhibits NF- κ B activation and specific activities may be cell or receptor context dependent. The deubiquitinase activity of A20 is thought to impair recruitment and/or retention of IKK to the CBM complex, by removal of K63-linked ubiquitin chains from MALT1 [19]. However, other studies in Jurkat T cells suggest A20 deubiquitinase function is not required for regulation of TCR induced NF- κ B. Rather, ZnF4/ZnF7 domains, that are required for binding to K63 and M1 chains surrounding the CBM complex, mediate the suppressive function of A20 [20]. In other cell types, A20 blocks TNF activation of IKK by binding polyubiquitin chains on the NEMO subunit of IKK and thereby prevent activation of IKK by

¹Institute of Immunity and Transplantation, Division of Infection and Immunity, University College London, The Pears Building, Hampstead, London, UK. ²VIB-UGent Center for Inflammation Research, UGent Department for Biomedical Molecular Biology, Unit of Molecular Signal Transduction in Inflammation, Gent, Belgium.

✉email: benedict.seddon@ucl.ac.uk

Received: 21 May 2024 Accepted: 16 September 2024

Published online: 26 September 2024

Tak1, a mechanism largely dependent on A20's seventh zinc-finger motif (ZnF7) [21]. Other studies suggest A20 competes with IKK for linear M1 ubiquitin chain binding using the ZnF7 domain [22, 23]. Enhancement of memory and/or effector T cell responses in the absence of A20 may be mediated by pro-survival functions of NF- κ B signalling. Optimal IL-2 synthesis by activated T cells is NF- κ B-dependent and promotes their survival [24] and addition of exogenous IL-2 can rescue defective Rel^{-/-} T cell responses to CD3 crosslinking in vitro [25–27]. Bcl-XL has also been suggested to be an important pro-survival target of NF- κ B during activation. In both mouse and human activated T cells, the expression of a dominant negative I κ B construct results in impaired Bcl-XL expression [28, 29]. However, the importance of this for survival is questioned by the observation that T cell-specific ablation of Bcl-XL does not result in death of activated T cells [30].

A further complication to studying NF- κ B pathways in T cells comes from the recent recognition that the IKK complex serves functions other than inducing NF- κ B. Ablation of the IKK complex, either by deletion of NEMO [14], or combined loss of IKK1 and IKK2 subunits [31] results in a developmental arrest in single positive (SP) thymocytes at the immature HSA^{hi} stage. Similar developmental blocks are observed in mice lacking the upstream activator of IKK, TAK1 [3, 32, 33]. In contrast, expression of NF- κ B REL subunits is not required for thymic development and generation of mature peripheral T cells [4, 34]. An explanation for this apparent contradiction comes from two key observations. First, the trigger for NF- κ B activation via IKK in developing thymocytes is not TCR but TNF. The CBM complex is not required for thymocyte development or selection signalling [11, 35]. In contrast, blockade of TNF signalling rescues development of IKK1/2 deficient thymocytes [31]. Second, recent studies reveal that the IKK complex has two functions during TNF signalling in T cells - activating NF- κ B and directly repressing cell death by inhibiting the serine threonine kinase, RIPK1. Ligation of TNFR1 causes recruitment of TRADD, TRAF2, and RIPK1. The ubiquitin ligases TRAF2, cellular inhibitor of apoptosis proteins (cIAPs) and the linear ubiquitin chain assembly complex (LUBAC), add ubiquitin chain modifications to themselves and RIPK1, creating a scaffold that allows recruitment and activation of the TAB/TAK and IKK complexes that in turn activate NF- κ B. This is termed complex I (reviewed in [36, 37]). A failure to maintain the stability of this complex results in the formation of cell death inducing complexes. In the presence of IAP inhibitors, IKK inhibitors or TAK1 inhibitors [38–40], a complex composed of TRADD, FADD, CASPASE-8 and RIPK1 forms that induces apoptosis, a function dependent upon RIPK1 kinase activity [37, 41, 42]. Phosphorylation of RIPK1 by IKK blocks RIPK1 kinase activity and therefore its capacity to induce apoptosis [40]. In thymocytes, it is this function of IKK, and not NF- κ B activation, that is critical for their survival and onward development and accounts for the phenotype observed in IKK deficiency [4]. A20 also appears to mediate cross-talk between NF- κ B and cell death signalling pathways. In MEFs, A20 protects cells from death by binding and stabilizing the linear (M1) ubiquitin network associated to Complex I. Deletion of A20 induces RIPK1 kinase-dependent and -independent apoptosis upon single TNF stimulation [43]. In T cells, A20 is proposed to protect cells from necroptotic cell death by restricting ubiquitination of RIPK3 and formation of RIPK1-RIPK3 complexes by its deubiquitinating motif [18].

In the present study, we investigated the role of IKK and NF- κ B signalling pathways during T cell activation by analysing responses by IKK2 deficient T cells, that exhibit impaired IKK activity. Our results reveal that IKK signalling is critical to protect blasts from cell death by both transcriptional and non-transcriptional mechanisms and identify the NF- κ B regulator A20 as a key target of NF- κ B signalling activation that specifically attenuates cell death signalling.

RESULTS

IKK2 deficient CD8 T cells exhibit impaired proliferative responses to antigen stimulation

To better understand the role of NF- κ B signalling pathways during T cell activation, we analysed antigen specific activation of IKK2 deficient T cells. In the absence of IKK2 expression, the IKK complex formed by IKK1 subunits is hypomorphic, but still sufficient to trigger canonical NF- κ B activation [14]. To analyse antigen specific responses in the absence of IKK2, we analysed the F5.Rag1^{-/-} huCD2^{iCre}/Ikk2^{lox} strain (F5/Ikk2 Δ T^{CD2} hereon) of TCR transgenic mice whose CD8⁺ T cells are specific for NP peptide from influenza, but lack IKK2 expression [44, 45]. We tested reactivity of control and IKK2 deficient F5 T cells in vitro, to titrations of specific peptide, and in vivo, following their adoptive transfer to WT hosts and intranasal challenge with influenza A viral (IAV). In vitro, reactivity of F5 T cells was profoundly defective in the absence of IKK2 expression. Fewer T cells were observed in division over a range of peptide doses, though those cells that were triggered to divide matched the burst of divisions observed in controls (Fig. 1A). In vivo, F5 Ikk2 Δ T^{CD2} T cells were activated in response to IAV infection, since they assumed a CD44^{hi}CD62L^{lo} effector memory phenotype, but failed to accumulate either in lymphoid tissues or at the site of infection in the lung (Fig. 1B). Together, these results suggest a profound defect in the ability of T cells to become activated and generate abundant effectors in the absence of IKK2.

Normal triggering, blast transformation and cell cycle progression in the absence of IKK2

The reduced proliferation of F5 Ikk2 Δ T^{CD2} T cells superficially resembled a failure of cells to be triggered following antigen recognition. To investigate this further, we examined early events of T cell activation in more detail. We first compared induction of CD69 and CD25 expression at 24 h following peptide challenge, to determine whether sensitivity of TCR signalling was altered in the absence of IKK2. We observed similar induction of these early markers of triggering by F5.Ikk2 Δ T^{CD2} and control T cells indicating that early activation events following TCR recognition were normal (Fig. 2A). Similarly, analysing cytokine production at this same time point revealed a similar capacity of cells to secrete the T cell growth factor, IL-2, important for subsequent blast transformation and proliferation, and the inflammatory factor, TNF, associated with effector differentiation. We next directly examined blast transformation, analysing cell size increases and induction of *Myc* mRNA at 24 h, in response to peptide challenge. Both these measures were similar between F5 Ikk2 Δ T^{CD2} T cells and controls (Fig. 2B), indicating that blast transformation was normal following antigen stimulation, in the absence of IKK2. We then examined cell cycle regulation in activated F5 T cells, comparing expression of key cell cycle regulators at 24 h following activation, just prior to onset of cell division, and kinetics of the first cell division following activation. Expression of mRNA for Cyclin D2 and D3, cyclin dependent kinase 6, *Skp2* and *E2f3* were all comparable between IKK2 deficient F5 T cells and controls. There was some evidence of a reduction in expression of cyclin dependent kinase inhibitor 1a in the absence of IKK2 (Fig. 2C). We compared the dynamics of cell cycle entry by measuring induction of Ki67 expression, that indicates entry of cells from G0 to G1 phase of cell cycle, DNA content to identify S phase and CTV cell dye labelling to identify cells that successfully complete first mitosis. In both control and IKK2 deficient T cell cultures, cells entered G1 between 18 h and 30 h, with a substantial fraction of these already in S phase by 30 h (Fig. 2D). First division was completed by most cells by 38 h. As indicated in earlier experiments, the fraction of F5 Ikk2 Δ T^{CD2} T cells undertaking cell division was reduced. Nevertheless, we found no evidence that priming, blast transformation or cell cycle dynamics were defective in F5 Ikk2 Δ T^{CD2} T cells. As such, the apparent proliferative defect must therefore be accounted for by defects in aspects of the T cell activation response other than cell cycle regulation.




Fig. 1 Defective activation of CD8⁺ F5 T cells in vitro and in vivo in the absence of IKK2. **A** CD8⁺ T cells were isolated from F5 *Ikk2ΔT*^{CD22} and Cre^{-ve} controls, labelled with CTV cell dye and stimulated in vitro with a range of NP68 peptide concentrations. At different times, cells were recovered and CTV profiles analysed. Histograms show CTV labelling by T cells stimulated for 72 h with NP68 at 10⁻⁹ M. Line graphs show mean divisions at 72 h over a range of peptide doses, and a time course of mean divisions, precursor frequency of cells triggered into division and burst size of dividing cells, from cultures stimulated with NP68 10⁻⁹ M. Data are representative (flow plots) or mean (line graphs) of 5 independent experiments. **B** CD8⁺ T cells from F5 *Ikk2ΔT*^{CD22} (*n* = 8) and Cre^{-ve} controls (*n* = 8) were transferred to CD45.1 WT hosts and challenged with IAV intranasally. 7 days later, lung, LN and spleen were recovered and CD45.2 donor T cell phenotype analysed. Density plots are of CD45.2 vs CD45.1 by CD8⁺TCR^{hi} cells, and CD62L vs CD44 expression by donor CD45.2 CD8⁺TCR^{hi} T cells recovered from lung. Bar charts show total numbers of donor F5 T cells of CD62L^{lo}CD44^{hi} TEM and CD62L^{hi}CD44^{hi} TCM phenotype recovered from spleen, lymph node and lung of the same mice. Data are representative of two independent experiments.

RIPK1 dependent cell death limits expansion of IKK2 deficient activated T cells

NF-κB has been implicated in controlling survival of T blasts by regulating intrinsic mitochondrial pathways of apoptosis through control of Bcl-XL expression [28, 29, 46]. We therefore asked

whether a cell death phenotype could account for the apparent proliferative defect of F5 *Ikk2ΔT*^{CD22} T cells. To do this, we assessed cell viability following T cell activation in vitro, by monitoring DNA content of cells. In cultures of control F5 T cells, a small fraction of dead cells was observed throughout the culture period. In contrast,




Fig. 2 Normal priming and entry into cell cycle following activation of IKK2 deficient T cells. $CD8^+$ T cells were isolated from F5 *Ikk2ΔT^{CD2}* and Cre $-ve$ controls, labelled with CTV cell dye and stimulated in vitro with a range of NP68 peptide concentrations. **A** Line graphs show percent of cells expressing CD25, CD69, TNF or IL-2 at 24 h of culture. **B** Density plots are of FSc vs Ssc of T cells following 24 h culture with NP68 at 10^{-9} M. **C** Viable cells were recovered from cultures at 24 h and RNA extracted. mRNA was analysed by bulk RNAseq. Bar chart shows Myc expression expressed as normalised FPKM (nFPKM) and cell cycle associated genes (**C**). **D** Cells stimulated with NP68 at 10^{-9} M were harvested from cultures at different times and analysed for Ki67 expression and DNA content by 7-AAD staining. Density plot shows Ki67 vs 7-AAD staining by live gated $CD8^+$ T cells in control cultures and gates used to define cells in G1 ($Ki67^{hi}$, diploid DNA content) and S + G2/M phase ($Ki67^{hi}$ > diploid DNA content). Histogram shows CTV labelling at 38 h and gates used to identify undivided cells and cells undergone 1 or more divisions. The line graphs are of precursor frequencies of undivided cells in G1 over time, vs cells in S + G2/M in undivided gate, vs cells that have completed their first division, changing with time for T cells from either Cre $-ve$ controls or F5 *Ikk2ΔT^{CD2}* donors. Data are representative of four (**A**, **B**) or six (**D**) independent experiments.

we observed a progressive and substantial accumulation of dead cells in cultures of IKK2 deficient cells, peaking around 30 h and significantly above levels observed in controls (Fig. 3A). Since NF- κ B signalling may be perturbed in F5 *Ikk2ΔT^{CD2}* T cells, it was possible that alterations in expression of regulators of intrinsic pathways of apoptosis could be responsible for increased death of F5 *Ikk2ΔT^{CD2}* T cells. However, analysing expression of key repressors, activators and facilitators of intrinsic apoptotic pathways did not identify any gross defects in their gene expression (Fig. 3B).

Since we did not observe obvious defects in regulation of intrinsic apoptotic pathways, we next considered whether cell death was triggered by extrinsic pathways of apoptosis. TNF receptor superfamily members with death domains in the cytoplasmic tail of the receptor, are able to induce formation of a caspase 8 dependent death inducing complex. In the case of TNFR1, this complex also includes the serine/threonine kinase, RIPK1, whose kinase activity facilitates formation and activation of the Caspase 8 dependent cell death complex. To test whether death of F5 *Ikk2ΔT^{CD2}* T cells was triggered by extrinsic cell death pathways, we activated IKK2 deficient F5 T cells in the presence of

RIPK1 kinase inhibitor, Necrostatin-1 (Nec1) [47]. Addition of Nec1 largely restored viability of activated F5 *Ikk2ΔT^{CD2}* T cells to levels observed in control cultures of $IKK2^{WT}$ F5 T cells (Fig. 3C), implicating RIPK1 dependent extrinsic cell death pathways in the death of IKK2 deficient T cells. To ask whether TNF was a trigger of extrinsic cell death in F5 *Ikk2ΔT^{CD2}* T cells, we generated F5 *Ikk2ΔT^{CD2}* *Tnf^{-/-}* mice. Loss of TNF expression by F5 *Ikk2ΔT^{CD2}* *Tnf^{-/-}* T cells also restored T cell viability following activation in vitro (Fig. 3C). Blocking RIPK1 dependent extrinsic cell death pathways not only rescued F5 *Ikk2ΔT^{CD2}* T cell viability, but also restored cell proliferation by IKK2 deficient F5 T cells to levels comparable with control $IKK2^{WT}$ F5 T cells, both in terms of fractions of cells successfully completing their first division (Fig. 3D) and the overall proliferative profiles later in cultures (Fig. 3E).

To confirm the relevance of these pathways in vivo, we tested whether loss of TNFR1 or RIPK1 kinase activity could rescue responses of F5 *Ikk2ΔT^{CD2}* T cells following IAV infection. We generated F5 *Ikk2ΔT^{CD2}* *Ripk1^{D138N}* mice expressing a kinase dead allele of RIPK1, and F5 *Ikk2ΔT^{CD2}* *Tnfrsf1a^{-/-}* mice that lacked expression of TNFR1. Measuring the response by different




Fig. 3 Induction of RIPK1 dependent cell death following activation of IKK2 deficient T cells. **A** CD8⁺ T cells were isolated from F5 *Ikk2ΔT^{CD2}* and Cre^{-ve} controls, labelled with CTV cell dye and stimulated in vitro with 10⁻⁹ M NP68 peptide. At different times during culture, T cells were recovered and stained for expression of Ki67 and DNA content by 7-AAD labelling. Density plots show Ki67 vs 7-AAD labelling at 38 h of culture by total CD8⁺ cells. Gates indicate dead cells with sub-diploid DNA content. Line graphs are of % sub diploid cells from total CD8⁺ gate at different times during culture for T cells from the indicated mice. **B** Expression of genes that regulate intrinsic apoptotic cell death pathway, determined by RNAseq. Data are from the same experiment described in Fig. 2B and C. **C** Line graphs are of % sub diploid CD8⁺ cells at different times after culture of T cells from F5 *Ikk2ΔT^{CD2}* and Cre^{-ve} controls, and cultures of F5 *Ikk2ΔT^{CD2}* T cells with addition of Necrostatin-1 (Nec1), and of similar cultures using T cells from F5 *Ikk2ΔT^{CD2}* and Cre^{-ve} littermate controls and F5 *Ikk2ΔT^{CD2}* *Tnfrsf1a^{-/-}* donors. **D** Entry of F5 T cells into cell cycle and completion of mitosis (Post d1) was analysed in cultures of T cells from F5 *Ikk2ΔT^{CD2}* donors in the presence and absence of Nec1. **E** Density plots are of CTV vs live/dead (L/D) on total CD8⁺ T cells, and CTV vs Ki67 by live CD8⁺ gated T cells in cultures at 72 h. **F** F5 T cells from the indicated strains were transferred to groups of CD45.1 hosts and infected i.n with IAV. At d7, mice were culled and phenotype/number of splenic T cells analysed. Density plots show donor CD45.2 vs host CD45.1 staining by live CD8⁺ T cells, and CD44 vs CD62L by donor CD45.2 F5 T cells from recipients of the indicated donor strains. Bar charts are of cell recovery of donor F5 T cells of T_{cm} and T_{em} phenotype from donor strains with the indicated combination of mutant alleles. Data are pool of three independent experiments (F).

F5.*Ikk2ΔT^{CD2}* T cells following transfer into IAV challenged WT hosts revealed a substantial rescue of responding F5 T cell numbers 7d after infection (Fig. 3F). Taken together, these data reveal that, following their activation, F5 T cells become sensitised to TNF induced, RIPK1 dependent cell death in the absence of IKK2 expression.

Reduced *Tnfrsf1a* expression by F5 *Ikk2ΔT^{CD2}* T cells following activation

The susceptibility of activated F5 *Ikk2ΔT^{CD2}* T cells to TNF induced RIPK1 dependent cell death was not predicted from earlier studies.

The complete loss of IKK function resulting from ablation of IKK1/2 renders thymocytes and mature T cells highly susceptible to TNF induced cell death [31, 48, 49]. However, expression of either IKK1 or IKK2 alone is sufficient to repress RIPK1 kinase activity and protect T cells. Accordingly, thymic development and peripheral naive T cell compartments are largely normal in mice whose T cells lack expression of only IKK1 or IKK2, in contrast to IKK1/2 deficient mice [4]. One way to reconcile the present observations in activated F5 T cells with earlier studies would be if IKK signalling in these TCR transgenic cells were for some reason different to that of CD8⁺ T cells in WT polyclonal mice, in such a manner that IKK1




Fig. 4 Impaired expression of *Tnfaip3* by IKK2 deficient T cells following antigen stimulation. CD8⁺ T cells isolated from F5 *Ikk2* Δ T^{CD2} and Cre -ve controls were cultured overnight with TNF and viability determined by viability dye staining. Control cells were additionally cultured with IKK2 inhibitor (IKK2i, 10 μ M) and Nec1 (10 μ M). **B** Volcano plot comparing gene expression of IKK2 deficient F5 T cells vs control F5 T cells 24 h after activation. **C** Barcode plot showing enrichment of the MsigDB gene set "HALLMARK_TNFA_SIGNALING_VIA_NFKB" in F5 *Ikk2* Δ TCD2 vs F5 CTRL groups. All genes are ordered from left to right on the x-axis by increasing logFC; genes most downregulated in F5 *Ikk2* Δ TCD2 are positioned on the left and genes most upregulated in F5 *Ikk2* Δ TCD2 are on the right. The black vertical bars indicate the positions of the genes within the gene set. The worm shows the relative enrichment of the vertical bars. The p value of the roast test for the gene set is indicated. **D** Bar charts show expression of NF- κ B gene targets specifically validated in T cells. Data are representative of three or more independent experiments (**A**).

alone is not able to repress RIPK1 triggered cell death in F5 T cells. To test this, we cultured naive F5 T cells with increasing doses of TNF to see whether cells were susceptible to TNF induced cell death. Neither control nor F5.*Ikk2* Δ T^{CD2} T cells were induced to undergo cell death even at supra-physiological concentrations of TNF, suggesting that IKK1 alone is sufficient to protect F5 T cells

(Fig. 4A). To further confirm that IKK signalling was required to protect F5 T cells from RIPK1 triggered cell death, we also tested whether IKK inhibitor could sensitise F5 T cells to TNF induced death. Addition of IKK inhibitor did indeed sensitise F5 T cells to TNF induced cell death even at low doses of TNF (Fig. 4A). Addition of Nec1 to cultures blocked cell death, confirming death

was RIPK1 dependent. Taken together, these results suggest that F5 *Ikk2ΔT^{CD2}* T cells become sensitive to TNF induced cell death following their activation, since naive F5 *Ikk2ΔT^{CD2}* T cells were resistant to TNF induced cell death. Development of sensitivity to TNF induced cell death must therefore result from changes in regulation of death signalling during T cell activation.

Our earlier studies show that TNFRSF induced NF-κB activation is reduced in F5 *Ikk2ΔT^{CD2}* T cells that only express IKK1 [45]. Therefore, we hypothesised that activated F5.*Ikk2ΔT^{CD2}* T cells fail to induce expression of NF-κB target gene(s) necessary to protect them from extrinsic cell death. To identify potential candidate genes we performed differential gene expression analysis of control and F5.*Ikk2ΔT^{CD2}* T cells 24 h after activation (Fig. 4B). Gene enrichment analysis confirmed the presence of an NF-κB target gene signature in control T cells that was reduced in F5 *Ikk2ΔT^{CD2}* T cells (Fig. 4C). However, a focused analysis of validated NF-κB gene targets specifically identified in IKK1/2 deficient thymocytes [4], revealed normal expression of many target genes by activated F5.*Ikk2ΔT^{CD2}* T cells. In thymocytes, expression of mRNA for *Nfkb2*, *Relb*, *Bcl3*, *Traf1*, *Birc2* and *Birc3* is NF-κB dependent, but were all normally expressed in activated F5.*Ikk2ΔT^{CD2}* T cells (Fig. 4D). This suggests that IKK1 mediated activation of NF-κB was in many cases sufficient for normal NF-κB dependent gene expression. There were, however, a number of defined NF-κB target genes in T cells whose expression was impaired in F5 *Ikk2ΔT^{CD2}* T cells, such as *Nfkb1a*, *Il2*, *Il7r* and *Tnfaip3*, which encodes A20 protein.

Defective A20 expression sensitises T cells to IKK dependent TNF induced cell death

The defect in *Tnfaip3* mRNA expression, which encodes the protein A20, was notable because A20 can inhibit NF-κB activation but is also implicated in regulating apoptotic and necroptotic cell death signalling in MEFs and T cells respectively [18, 43]. To investigate which of these functions was relevant in activated T cells in our studies, we first analysed T cells from *Tnfaip3^{fllox} Cd4^{Cre}* (*Tnfaip3ΔT^{CD4}*) mice whose T cells lack A20 expression. Consistent with earlier studies, we found that, while total T cell numbers were largely normal in the absence of A20, there were significant increases in numbers of CD4 memory and Foxp3⁺ regulatory T cell populations (Fig. 5A). Treg numbers were also increased in the thymus, suggesting enhanced production in the absence of A20. TCR triggered NF-κB signalling is implicated in generation of both regulatory T cells and CD4 memory populations, so the observed increases were consistent with a disinhibition in NF-κB signalling in the absence of A20. We have previously shown that NF-κB activation by TNFRSF members is important for induction of *Il7r* expression and naive T cell survival [45]. Analysing naive T cell numbers and IL7R protein did not, however, reveal any evidence of a comparable de-repression of NF-κB signalling downstream of TNFRSF in *Tnfaip3ΔT^{CD4}* mice.

In MEFs, A20 binds and stabilizes the linear (M1) ubiquitin network associated to complex I, thereby inhibiting complex II formation and TNF induced cell death [23, 43]. Since TNF induced cell death of IKK2 deficient effectors was RIPK1 dependent, we first analysed RIPK1 recruitment and ubiquitination in TNFR complex I in A20 deficient T cells. Total thymocytes from control and *Tnfaip3ΔT^{CD4}* mice were stimulated with FLAG-TNF and complex I immunoprecipitated at different timepoints following stimulation. Blotting for RIPK1 revealed the dynamics of RIPK1 ubiquitination over time. Analysing WT thymocytes revealed heavy ubiquitination of RIPK1 that gradually declined at later timepoints (Fig. 5B). A20 deficient thymocytes exhibited similar levels and extent of ubiquitination of RIPK1 following stimulation as WT. To specifically assess linear ubiquitin chains, thymocytes were stimulated with TNF and complexes with linear ubiquitin were immunoprecipitated with a HALO-NEMO construct, that preferentially, though not exclusively, binds M1 ubiquitin [50]. Blotting for M1 ubiquitin revealed that the linear (M1) ubiquitin network is reduced in

T cells in the absence of A20 (Fig. 5B). Nevertheless, ubiquitination of RIPK1 and recruitment of IKK1 was broadly similar between WT and A20 deficient T cells.


Analysing NF-κB nuclear translocation following TNF stimulation revealed similar levels of NF-κB activation in A20 deficient T cells as controls, but with some evidence of more sustained nuclear levels than observed in WT cells (Fig. 5C). We also analysed viability of A20 deficient T cells following TNF stimulation. In contrast to MEFs, A20 deficient T cells remained resistant to TNF induced cell death (Fig. 5D). Since IKK activity is essential to repress RIPK1 mediated cell death in T cells, we measured survival of A20 deficient T cells with TNF when IKK was inhibited. Titration of IKK2 inhibitor revealed that A20 deficient T cells were highly sensitive to IKK inhibition compared with controls (Fig. 5E), and were similarly highly sensitive to low levels of TNF with suboptimal panIKK inhibition (Fig. 5F). Cell death in vitro was blocked by Nec1, confirming RIPK1 dependence. Taken together, these data suggested that in the absence of A20 expression, the capacity of IKK to repress RIPK1 induced cell death is greatly impaired, such that even partial loss of IKK function and very low levels of TNF are sufficient to induce cell death.

A20 is critical for survival of IKK2 deficient T cells in vivo

Our analysis of A20 deficient T cells suggested that IKK dependent repression of RIPK1 is highly dependent upon A20 for optimal activity. To test for evidence of epistasis between *Tnfaip3* and *Ikkb2* in vivo, we generated *Ikkb2^{fllox} Tnfaip3^{fllox} Cd4^{Cre}* (*Tnfaip3.Ikk2ΔT^{CD4}*) mice whose T cells lack expression of both IKK2 and A20 protein. In mice lacking one or other of A20 or IKK2, thymic development is normal and T cell compartments are largely normal in size, other than a modest reduction in the naive CD8 compartment in *Ikkb2^{fllox} Cd4^{Cre}* mice (Fig. 6A, B) that has been previously reported [4, 14, 45]. Analysing thymic of *Tnfaip3.Ikk2ΔT^{CD4}* mice first, revealed normal representation of most major DP and SP subsets. However, a small but significant reduction in the most mature CD62L^{hi}HSA^{lo} stage of CD8 T cell development was evident, both in terms of absolute numbers and as a fraction of total CD8SPs (Fig. 6A). In contrast, quantifying peripheral T cell compartments revealed a potent epistatic interaction between *Tnfaip3* and *Ikkb2*. As compared with controls or single knockout strains, ablation of both IKK2 and A20 resulted in profound lymphopenia in both CD4⁺ and CD8⁺ T cell subsets (Fig. 6B). *Ikk2ΔT^{CD4}* mice exhibit reduced numbers of both Treg and CD4⁺ memory compartments, attributed to the hypomorphic function of IKK complex in the absence of IKK [14, 24]. Of note, additional loss of A20 in *Tnfaip3.Ikk2ΔT^{CD4}* mice resulted in increases in both these subsets, suggesting that the derepression of NF-κB activity observed in A20 deficient mice that boosts these subsets also occurred with hypomorphic IKK in IKK2 deficient mice (Fig. 6B).

We next asked whether the T lymphopenia in *Tnfaip3.Ikk2ΔT^{CD4}* mice was the result of a RIPK1 induced cell death process, by testing if kinase dead RIPK1^{D138N} could reverse lymphopenia. To do this we generated and analysed *Tnfaip3.Ikk2ΔT^{CD4} Ripk1^{D138N}* mice. In vivo inactivation of RIPK1 kinase activity resulted in a near complete reversal of T lymphopenia in *Tnfaip3.Ikk2ΔT^{CD4}* mice. Numbers and representation of mature CD62L^{hi}HSA^{lo} CD8 SP thymocytes were restored by introduction of RIPK1^{D138N} mutation (Fig. 6A). Similarly, RIPK1^{D138N} mutation restored numbers of naive CD4⁺ and naive CD8⁺ T cells in *Tnfaip3.Ikk2ΔT^{CD4}* mice to near normal levels, confirming the dominant role of extrinsic cell death processes in the lymphopenia of *Tnfaip3.Ikk2ΔT^{CD4}* mice.

Taken together, these data suggest a powerful synergy between IKK2 and A20 in regulating resistance to cell death not evident in single deficient strains. Since A20 deficient T cells were more sensitive to TNF induced cell death in vitro (Fig. 5), we hypothesised that A20 was required to facilitate efficient repression of RIPK1 by IKK. We first confirmed that the ubiquitin



network that is induced by TNFR signalling was perturbed in IKK2/A20 deficient T cells in the same way as A20 single deficient T cells. Analysing RIPK1 ubiquitination and M1 linear network in TNF stimulated thymocytes from *Tnfaip3.Ikk2ΔT^{CD4}* mice revealed similar patterns of complex formations as observed in thymocytes

from *Tnfaip3ΔT^{CD4}* mice (Supplementary Fig. 2). Next, if A20 was acting in the same pathway as IKK, whether upstream or downstream, the impact of A20 ablation on cell death should be dependent on IKK activity. Therefore, in the complete absence of IKK, further A20 ablation would not be expected to have further

Fig. 5 Normal NF- κ B activation but defective regulation of extrinsic cell death pathways in *Tnfaip3* deficient T cells. **A** Lymph nodes and spleen were recovered from *Tnfaip3 Δ ^{CD4}* ($n = 6$) and Cre -ve litter mates ($n = 15$) aged between 8 and 12 weeks, and T cell phenotype and number determined by flow cytometry. Density plots are of CD4 vs CD8 expression by total live lymph node cells, CD25 vs CD44 by the indicated subset. Bar charts summarise total numbers of TCR^{hi}CD4⁺ memory phenotype (CD4⁺CD44^{hi}Foxp3⁻), T_{reg} (CD25⁺Foxp3⁺ Treg), CD4⁺TCR^{hi}CD44^{lo} naive T cells (CD4 naive) and CD8⁺TCR^{hi}CD44^{lo} naive T cells (CD8 naive) recovered from total lymph nodes and spleen combined. Total numbers of CD25⁺Foxp3⁺ thymic Treg are from thymus. Bar chart of IL-7R expression by naive CD4 and naive CD8 T cells is expressed as fraction of MFI normalised to MFI of corresponding subset from Cre -ve controls. **B** Thymocytes from *Tnfaip3 Δ ^{CD4}* and Cre -ve litter mates were stimulated with FLAG-TNF or hTNF for different times, lysed and immunoprecipitated with either anti-FLAG-sepharose or HALO-NEMO beads and analysed by immunoblotting for RIPK1, M1 ubiquitin and IKK1. Uncropped immunoblots are shown in Supplementary Fig. 1. **C** Total thymocytes from *Tnfaip3 Δ ^{CD4}* and Cre -ve litter mates were stimulated with TNF for upto 16 hr, nuclear extracts prepared and RELA levels determined by ELISA. **D–F** Lymph node cells from *Tnfaip3 Δ ^{CD4}* and Cre -ve litter mates were cultured overnight with titrations of TNF, IKK2 inhibitor (IKK2i), in the presence or absence of fixed concentrations of TNF (20 ng/ml), Nec1 (10 μ M), pan IKK inhibitor (IKK16, 0.25 μ M). Line graphs show fraction of dead cells amongst TCR^{hi} naive CD4⁺CD44^{lo} and TCR^{hi} naive CD8⁺CD44^{lo} T cells from *Tnfaip3 Δ ^{CD4}* and Cre -ve litter mates from cultures titrating TNF (**D**), in cultures titrating IKK2i in the presence or absence of Nec1 and/or TNF (**E**) and in cultures titrating TNF with addition of Nec1 and or IKK16 (**F**). Data are representative (**A–C**) or show average of three or more independent experiments. Error bars show SEM. Uncropped gels from (**B**) are in Supplementary Fig. 1.

impact. To test this, we generated *Chuk^{fllox} Ikkkb^{fllox} Tnfaip3^{fllox} CD4^{Cre} (Ikk1.Ikk2.Tnfaip3 Δ ^{CD4})* mice that lack expression of both the IKK complex and A20. If A20 is in fact acting independently of IKK, we would expect an additional impact of A20 deficiency upon IKK deficiency, as observed when comparing *Ikk2 Δ ^{CD4}* and *Tnfaip3.Ikk2 Δ ^{CD4}* strains. In mice lacking IKK1/2 expression, thymic development was profoundly blocked at the mature SP stage, and mice had reduced numbers peripheral naive T cells (Fig. 6C), as previously reported [14, 31]. Analysing *Ikk1.Ikk2.Tnfaip3 Δ ^{CD4}* mice that lack A20 and the IKK complex, revealed a phenotype indistinguishable from that of *Ikk1.Ikk2 Δ ^{CD4}* mice. Additional loss of A20 did not further exacerbate the phenotype of *Ikk1.Ikk2 Δ ^{CD4}* mice, suggesting that the A20 pro-survival function in T cells was dependent upon IKK activity and that A20 and IKK were in a common pathway to control cell death.

Accelerated cell death of activated T cells lacking both IKK2 and A20

Following T cell activation, TCR induced MALT1 activity targets A20 for degradation [19, 51]. Our data suggested that IKK2 deficient T cells fail to successfully induce re-expression of A20, resulting in their sensitisation to RIPK1 dependent cell death. To validate this, we analysed survival of A20/IKK2 deficient T cells following activation to determine whether their behaviour phenocopied that of activated IKK2 deficient T cells. T cells were isolated from *Ikk2 Δ ^{CD4}*, *Tnfaip3.Ikk2 Δ ^{CD4}* and *Tnfaip3.Ikk2 Δ ^{CD4} Ripk1^{D138N}* mice, labelled with CTV cell dye and activated by plate bound CD3 and CD28. Analysing proliferation and cell death revealed the anticipated impairment of T cell viability amongst both CD8⁺ and CD4⁺ T cells from *Ikk2 Δ ^{CD4}* mice. Consistent with experiments analysing peptide specific activation of IKK2 deficient F5 T cells, we did not observe substantial RIPK1 dependent cell death at 24 h. However, by 48 h, cultures of IKK2 deficient CD4⁺ and CD8⁺ T cells exhibited low levels of viability that could be restored by inhibiting RIPK1 with Nec1 (Fig. 7). By comparison, T cells from *Tnfaip3.Ikk2 Δ ^{CD4}* mice exhibit high levels of cell death even by 24 h, that were blocked by introduction of kinase dead RIPK1^{D138N}. By 48 h, levels of death in cultures of T cells from *Tnfaip3.Ikk2 Δ ^{CD4}* mice resembled those from *Ikk2 Δ ^{CD4}* mice.

DISCUSSION

In this study, we investigated the roles of NF- κ B and cell death signalling following T cell activation, in the development of effector responses specifically following initial T cell priming, which is strictly NF- κ B dependent. IKK2 deficient T cells provide a sensitised model of hypomorphic IKK signalling during T cell activation, in which reduced IKK activity is sufficient for initial priming, but revealed adaptive regulation of extrinsic cell death pathways, mediated by NF- κ B dependent control of the gene for A20, *Tnfaip3*. Our results

suggest a new function for A20 in the regulation of extrinsic cell death pathways in T cells, by facilitating optimal repression of RIPK1 mediated cell death by IKK complex and that is controlled by NF- κ B dependent expression of *Tnfaip3* during activation.

Our previous work showed that IKK signalling is essential for survival of mature thymocytes, by phosphorylating and thereby repressing the kinase activity of RIPK1. In the absence of IKK activity, thymocytes die by TNF induced RIPK1 triggered apoptosis [4]. In thymocytes and naive T cells, it appears that even suboptimal IKK activity is sufficient for this survival function, since hypomorphic IKK complexes that form in the absence of either IKK1 or IKK2 expression, are sufficient to maintain control RIPK1 dependent cell death. Mice with T cell specific deletion of *Ikk1* or *Ikk2* exhibit normal thymocyte and peripheral T cell survival [4]. In confirmation, we found here that IKK2 deficient naive F5 T cells were resistant to TNF induced cell death even at supra-physiological levels of TNF. On this basis, the observed susceptibility of IKK2 deficient T cells to RIPK1 dependent TNF induced cell death following activation was not predicted, but revealed a transcription dependent re-configuration of extrinsic cell death pathways, following T cell activation, that heightened sensitivity of T cells to RIPK1 dependent cell death and a more stringent requirement for repression by IKK activity. In regard to the specific mode of cell death involved, our earlier work showed that RIPK1 triggered apoptotic cell death in the absence of IKK, since thymocytes do not express *Mlkl* and are not capable of undergoing necroptosis. In contrast, activated T cells are capable of necroptotic cell death in the absence of either FADD or CASPASE8 [52, 53], which is MLKL dependent and not associated with DNA fragmentation [54]. Although we did not test whether cell death of IKK2 deficient T cells was MLKL dependent, we did observe DNA fragmentation, that was used to define dead cells, that was prevented by RIPK1 inhibition. Furthermore, while CASPASE8 and FADD deficiencies have little impact on naive T cells, that do not express *Mlkl*, we found that loss of A20 and IKK2 expression in T cells resulted in a profound loss of naive T cells. Therefore, the weight of evidence suggests that IKK2 is regulating apoptotic cell death in both resting and activated T cells, at least in the context of normal CASPASE8 activity and function.

NF- κ B activation has been implicated in regulating survival of many cell types, including T cells, by tuning expression of Bcl2 family members that control the intrinsic mitochondrial pathway of cell death. Results here and from previous studies of IKK2 deficient T cells [45] did not find evidence of perturbed mitochondrial cell death regulation. We observed only a modest reduction of Bcl2 family member A1 expression in activated IKK2 deficient T cells, although A1 is not thought to be required for survival of activated T cells [55]. Our results do not necessarily exclude a role for regulation of intrinsic cell death pathways by NF- κ B in activated T cells, since we were studying cells with




Fig. 6 *Tnfaip3* expression by IKK2 deficient T cells is crucial for repression of RIPK1 induced cell death. Thymus, lymph nodes and spleens were recovered from *Tnfaip3* Δ T^{CD4} ($n = 6$), *Ikk2* Δ T^{CD4} ($n = 4$), *Tnfaip3.Ikk2* Δ T^{CD4} ($n = 11$), *Tnfaip3.Ikk2* Δ T^{CD4} RIPK1^{D138N} ($n = 8$), *Ikk1.Ikk2* Δ T^{CD4} and *Tnfaip3.Ikk1.Ikk2* Δ T^{CD4} mice between 10 and 16 weeks of age. WT mice were a pool of Cre-ve littermates ($n = 15$). Composition and size of T cell compartments was determined by flow cytometry. **A** Density plots are of CD4 vs CD8 by total live thymocytes, HSA vs CD62L by CD4⁺CD8⁺TCR^{hi} (CD4 SP thymocytes) and CD4⁺CD8⁺TCR^{hi} (CD8 SP thymocytes) from the indicated strains. Bar charts show total numbers of the indicated subset in different strains, and for CD8 SP thymocytes, the frequency of mature HSA^{lo} thymocytes amongst total CD8 SP thymocytes. **B** Density plots are of CD4 vs CD8 by total live lymph node cells, CD25 vs CD44 by gated CD4⁺TCR^{hi} (CD4⁺ T cells) and CD8⁺TCR^{hi} (CD8⁺ T cells) cells from lymph nodes of the indicated strains. Bar charts show total numbers recovered from lymph nodes and spleen combined, of the indicated subsets in different strains, and IL-7R expression level, expressed as a fraction of the same subset from Cre -ve controls analysed on the same day, for CD4⁺CD44^{lo} and CD8⁺CD44^{lo} naive T cells recovered from lymph nodes. **C** Bar charts show cell numbers of thymic subsets of CD4 and CD8 SPs, and peripheral CD4⁺CD44^{lo} (CD4⁺ naive) and CD8⁺CD44^{lo} (CD8⁺ naive) T cells recovered from *Ikk1.Ikk2* Δ T^{CD4} ($n = 4$), *Tnfaip3.Ikk1.Ikk2* Δ T^{CD4} ($n = 10$) and Cre-ve littermates mice ($n = 7$).

hypomorphic IKK rather than a complete absence, so could in principle reflect variation in the thresholds of NF- κ B activity required to regulate expression of different target genes. Our previous studies of REL and IKK deficient T cells identified a number of genes whose expression was NF- κ B dependent in T cells in vivo [4, 31]. While it is clear that activation of NF- κ B is suboptimal in either IKK1 or IKK2 deficient T cells [14, 31], we found that expression of many NF- κ B gene targets, including *Myc* that is required for blast transformation, and *Ciap1/2*, required for survival, were normally expressed in IKK2 deficient T cells following activation. In contrast, *Il7r*, and negative regulators of

NF- κ B signalling, *Ikbia*, *Ikbie* and most notably *Tnfaip3*, were reduced in just the absence of IKK2. Our results reveal a hierarchy of NF- κ B target gene regulation in T cells, with a subset of target genes exhibiting a higher threshold of NF- κ B transcriptional activity required for optimal expression. Therefore, regulation of activated T cell survival by NF- κ B is likely multifaceted, with different layers of regulation mediated by both low threshold (*Myc*, *Ciap1/2*) and high threshold targets (*Il7r* and *Tnfaip3*).

Following activation, IKK2 deficient T cells lost control of RIPK1, resulting in cell death. We ascribe a transcriptional mechanism to this change in death signalling, resulting from a failure of




Fig. 7 Accelerated cell death of activated T cells lacking IKK2 and A20. T cells from lymph nodes of *Ikk2ΔT^{CD4}*, *Tnfaip3.Ikk2ΔT^{CD4}*, *Tnfaip3.Ikk2ΔT^{CD4}RIPK1^{D138N}* strains, and Cre^{-ve} litter mates were labelled with CTV and activated in vitro with plate bound anti-CD3 and CD28. Viability of CD4⁺ and CD8⁺ T cells was assessed at 24 h and 48 h of culture by flow cytometry. T cells from *Ikk2ΔT^{CD4}* donors were additionally cultured with and without Nec1 (10 μM). **A** Density plots are of Live/dead dye vs CTV dilution profile of total CD4⁺ or CD8⁺ T cells from the indicated strains at 48 h **(B)** Bar charts show % live cells in cultures of the indicated T cell subset from the indicated strain and condition at either 24 h or 48 h post activation. Data are representative **(A)** or mean ± SEM **(B)** of four independent experiments.

activated IKK2 deficient T cells to restore NF-κB dependent expression of *Tnfaip3*. Analysing T cells lacking A20 revealed a novel function of this key regulator in controlling extrinsic cell death pathways, regulating the IKK-RIPK1 signalling axis. In other cell types, A20 is implicated in regulating both NF-κB activity and cell death and so a loss of *Tnfaip3* expression following activation of IKK2 deficient T cells could have had one of several outcomes. In T cells, there is clear evidence from A20 deficient mice for a loss of negative feedback regulation of NF-κB activation in vivo, since Treg and CD4⁺ memory phenotype cells are increased in number and there are several reports of enhance effector function by A20 deficient T cells in vivo [16, 56]. Notably, both these subsets and functions rely upon TCR triggered NF-κB [6]. It appears that in T cells, the negative feedback function of A20 may be most

apparent in the context of TCR rather than TNF induced NF-κB, which connect to NF-κB activation by formation of distinct complexes. Although both Treg and CD4 memory cells are reduced in number in IKK2 deficient mice, additional loss of A20 resulted in a modest restoration of numbers. This demonstrates that even suboptimal NF-κB activation by hypomorphic IKK activity in these mice was subject to derepression in the absence of A20. We did not, however, observe any evidence that TNF induced NF-κB activity or expression of gene targets such as IL7R, was increased in T cells in the absence of A20 in vivo, although there was some evidence of more sustained nuclear translocation of RELA following TNF stimulation of cells in vitro.

In regards to control of cell death pathways, A20 has been implicated as a key regulator in MEFs, mediated by binding and

stabilization of the M1 linear ubiquitin network associated with complex I. Deletion of A20 appears to be sufficient to destabilise the M1 ubiquitin network resulting in both RIPK1 kinase-dependent and -independent apoptosis upon TNF stimulation [43]. In T cells, we also observed highly defective formation of the M1 ubiquitin network. However, in contrast to MEFs, A20 deletion and the consequent defects in the ubiquitin network were not sufficient to destabilise complex I formation to the point of death, since *Tnfrsf1a*^{CD4} mice had normal T cell numbers and were not more sensitive to TNF induced death in vitro. However, further stressing T cells with suboptimal levels of IKK inhibitors was sufficient to reveal fundamental frailties in cell death control. In IKK2 deficient T cells, loss of A20 in both resting naive T cells or in activated T cells rendered cells highly susceptible to TNF induced apoptosis. In this context, cell death was entirely RIPK1 dependent, contrasting with the impact of A20 deficiency in MEFs which also triggered RIPK1 independent death. In T cells, the pro-survival function of A20 was entirely dependent on IKK kinase activity since A20 ablation had no additional impact on cell viability in the complete absence of IKK expression. This suggests that in T cells, A20 promotes cell survival by facilitating repression of RIPK1 by IKK. Precisely how A20 achieves this is not clear. IKK recruitment to complex I and induction of NF- κ B appear normal in T cells in the absence of A20. Furthermore, we show that recruitment of RIPK1 to complex I and its ubiquitination does not depend upon A20. However, the M1 linear ubiquitin network is clearly compromised in the absence of A20. One function of this network, therefore, may be to permit optimal co-localisation of IKK and RIPK1 within complex I to allow efficient phosphorylation of RIPK1.

Our results also shed light on the dynamics and triggers of NF- κ B signalling during T cell activation. Initial TCR stimulation is required to activate T cells, and induction of NF- κ B targets such as Myc are critical for early events such as blast transformation. However, our data also clearly demonstrate the activity of TNF induced signalling later in the response, revealed by cell death events in the absence of IKK2 expression. However, in normal T cells, such TNF stimulation likely also triggers NF- κ B activation and provides a second wave of transcriptional activity after the initial TCR induced activation. These distinct waves of NF- κ B activity may contribute to the apparent hierarchy of NF- κ B target gene regulation we observed here, especially if TCR and TNF induced NF- κ B exhibit distinct requirements and thresholds of IKK activation. This is a possibility given that the ubiquitin scaffolds that form following TCR induced CBM complex formation and TNFR complex I represent highly distinct structures that may vary with their capacity to recruit TAB/TAK and IKK complexes and trigger downstream NF- κ B activation. In this context, it may be significant that in vivo, RIPK1 inactivation only partially rescues the T cell response by IKK2 deficient F5 T cells. This suggests that the reduced T cell response is the result of suboptimal NF- κ B activation in the absence of IKK2, so our data show that, in addition to regulation of cell death pathways, IKK2 dependent activation of NF- κ B is also important for optimal effector expansion in vivo. Identifying the relevant NF- κ B targets that mediate this function will be important area of future investigation.

MATERIALS AND METHODS

Mice

Mice with the following mutations were used in this study; conditional alleles of *Ikkkb* [57], *Chuk* [58], *Tnfrsf1a* [59], *Cre* transgenes expressed under the control of the human CD2 (*huCD2*^{Cre}) [60] or *Cd4* expression elements (*Cd4*^{Cre}), mice with null mutations for *Tnf*, *Rag1*, *Tnfrsf1*, (Jax Laboratories) mice expressing F5 TCR transgenes44, mice with a D138N mutation in *Ripk1* (RIPK1^{D138N}) [61]. The following strains using combinations of these alleles were bred; F5 *Rag1*^{-/-} *Ikkkb*^{fx/fx} *huCD2*^{Cre} (F5 *Ikk2ΔT*^{CD2}), F5 *Rag1*^{-/-} *Ikkkb*^{fx/fx} *huCD2*^{Cre} *Tnfrsf1a*^{-/-} (F5 *Ikk2ΔT*^{CD2} *Tnfrsf1a*^{-/-}), F5 *Rag1*^{-/-} *Ikkkb*^{fx/fx} *huCD2*^{Cre} *Ripk1*^{D138N} (F5 *Ikk2ΔT*^{CD2} *RIPK1*^{D138N}), F5 *Rag1*^{-/-} *Ikkkb*^{fx/fx} *huCD2*^{Cre} *Tnf*^{-/-} (F5 *Ikk2ΔT*^{CD2} *Tnf*^{-/-}), *Tnfrsf1a*^{CD4} *CD4*^{Cre} (*Tnfrsf1ΔT*^{CD4}), *Ikkkb*^{fx/fx} *Cd4*^{Cre} (*Ikk2ΔT*^{CD4}), *Tnfrsf1a*^{CD4} *Ikkkb*^{fx/fx}

CD4^{Cre} (*Tnfrsf1ΔT*^{CD4}), *Tnfrsf1a*^{CD4} *Ikkkb*^{fx/fx} *CD4*^{Cre} *Ripk1*^{D138N} (*Tnfrsf1ΔT*^{CD4} *RIPK1*^{D138N}), *Tnfrsf1a*^{CD4} *Chuk*^{fx/fx} *Ikkkb*^{fx/fx} *CD4*^{Cre} (*Tnfrsf1ΔT*^{CD4}), SJL.C57Bl6/J (CD45.1). All mice were bred in the Comparative Biology Unit of the Royal Free UCL campus and at Charles River laboratories, Manston, UK. A/NT/60-68 Influenza A virus was inoculated into mice either by intranasal or intraperitoneal routes at a dose of SHAU/mouse. Animal experiments were performed according to institutional guidelines, local ethical review and in accordance with Home Office regulations under PPL PP2330953. Comparisons of mouse genotypes were based on minimally six mice/group from minimally three independent analyses, unless stated otherwise. Both male and female mice were used throughout as they naturally occurred across genotypes. Different genotypes were often, though not explicitly, analysed blind.

Flow cytometry and electronic gating strategies

Flow cytometric analysis was performed with 2–5 × 10⁶ thymocytes, 1–5 × 10⁶ lymph node or spleen cells. Cell concentrations of thymocytes, lymph node and spleen cells were determined with a Casy Cell Counter (OMNI Life Science). Cells were incubated with saturating concentrations of antibodies in 100 μl of Dulbecco's phosphate-buffered saline (PBS) containing bovine serum albumin (BSA, 0.1%) for 1 h at 4 °C followed by two washes in PBS-BSA. Panels used the following mAb: APC-conjugated antibody against CD24 (ThermoFisher Scientific), EF450-conjugated antibody against CD25 (ThermoFisher Scientific), PE-conjugated antibody against CD127 (ThermoFisher Scientific), BV785-conjugated CD44 antibody (Biolegend), BV650-conjugated antibody against CD4 (Biolegend), BUV395-conjugated antibody against CD8 (BD Biosciences), BUV737-conjugated antibody against CD62L (BD Biosciences), PerCP-cy5.5-conjugated antibody against TCR (Tonbo Biosciences), APC-conjugated antibody against FoxP3 (ThermoFisher Scientific), FITC-conjugated antibody against Ki67 (ThermoFisher Scientific), CD45.1-conjugated antibody against BV650 (Biolegend), CD45.2 antibody conjugated against PE (Biolegend), CD69-conjugated antibody against PE/Dazzle (Biolegend). Cell viability was determined using LIVE/DEAD cell stain kit (Invitrogen Molecular Probes), following the manufacturer's protocol. Multi-colour flow cytometric staining was analysed on a LSRFortessa (Becton Dickinson) instrument, and data analysis and colour compensations were performed with FlowJo V10 software (Becton Dickinson). The following gating strategies were used: Naive peripheral CD4⁺ T cells - CD4⁺ TCR^{hi} CD44^{lo} CD25^{lo}, naive peripheral CD8⁺ T cells - CD8⁺ TCR^{hi} CD44^{lo} CD25^{lo}, memory phenotype CD4⁺ T cells - CD4⁺ TCR^{hi} CD44^{hi} Foxp3⁻, regulatory T cells - CD4⁺ TCR^{hi} Foxp3⁺, mature CD4⁺ and CD8⁺ SP thymocytes were identified as TCR^{hi} CD4⁺ CD8⁻ HSA^{lo} and TCR^{hi} CD4⁻ CD8⁺ HSA^{lo} respectively.

In vitro culture

Thymocytes and LN T cells were cultured at 37 °C with 5% CO₂ in RPMI-1640 (Gibco, Invitrogen Corporation, CA) supplemented with 10% (v/v) fetal bovine serum (FBS) (Gibco Invitrogen), 0.1% (v/v) 2-mercaptoethanol (Sigma Aldrich) and 1% (v/v) penicillin-streptomycin (Merck) (RPMI-10). Recombinant TNF was supplemented to cultures at 20 ng/ml, unless otherwise stated, and was obtained from Peprotech, with PBS used as vehicle. Inhibitors were used at the following concentrations, unless otherwise stated: IKK2 inhibitor BI605906 (IKK2i) (10 μM in 0.1% DMSO vehicle), IKK16 (2 μM in 0.1% DMSO), Nec1 (10 μM in 0.1% DMSO). Binding of RelA from nuclear extracts of TNF-stimulated thymocytes to NF- κ B oligonucleotide was determined by specific ELISA (Active Motif) according to the manufacturer's instructions.

Prior to activation, T cells were labelled with CTV (ThermoFisher Scientific) cell dye and cells culturing at 10⁶/ml in 96 well plates. F5 T cells were activated by a nonamer antigenic peptide from human influenza virus nucleoprotein (NP) of the 1968 strain A/HK/8/68 (residues 366–374: ASNENMDAM; peptide NP68), together with splenocytes from *Rag1*^{-/-} hosts as APCs, while polyclonal T cells activated by CD3 (1 μg/ml) and CD28 (1 μg/ml) mAb (BD Pharmingen) bound to 96 well plates for 2 h at 37 °C and washed with PBS prior to culture. TNF and IL-2 cytokine secretion was assessed by intracellular staining following 4 hr culture with PMA/ionomycin and brefeldin A, as previously described [62].

RNAseq analysis

RNA was isolated from single cell suspensions using the RNeasy Mini Kit (Qiagen) according to the manufacturer's instructions. RNA integrity was confirmed using Agilent's 2200 TapeStation. Samples were processed using

the SMART-Seq v4 Ultra Low Input RNA Kit (Clontech Laboratories, Inc.). Briefly, cDNA libraries were generated using the SMART (Switching Mechanism at 5' End of RNA Template) technology which produces full-length PCR amplified cDNA starting from 10 ng total RNA. The amplified cDNA was checked for integrity and quantity on the Agilent Bioanalyser using the High Sensitivity DNA kit. 150 pg of cDNA was then converted to sequencing library using the Nextera XT DNA (Illumina, San Diego, US). This uses a transposon able to fragment and tag the double-stranded cDNA (Tagmentation), followed by a limited PCR reaction (12 cycles). Libraries to be multiplexed in the same run are pooled in equimolar quantities, calculated from Qubit and TapeStation fragment analysis. Samples were sequenced on the NextSeq 500 instrument (Illumina, San Diego, US) using a 43 bp paired end run.

Run data were demultiplexed and converted to fastq files using Illumina's bcl2fastq Conversion Software v2.19. Fastq files are pre-processed to remove adapter contamination and poor quality sequences (trimmomatic v0.36) before being mapped to a suitable reference genome using the spliced aligner STAR (v2.5b). Mapped data is deduplicated using Picard Tools (v2.7.1), in order to remove reads that are the result of PCR amplification, and remaining reads per transcript are counted by FeatureCounts (v1.4.6p5). Normalisation, modelling and differential expression analysis are then carried out in R using edgeR and limma. For gene-set testing, the Molecular Signatures Database (MSigDB) Hallmark gene sets mapped to mouse ortholog genes were downloaded from the Walter and Eliza Hall Institute for Medical Research Bioinformatics webpage (<https://bioinf.wehi.edu.au/MSigDB/index.html>, downloaded on 29/11/2021). The limma roast function with 9999 rotations was used to test the "HALLMARK_TNFA_SIGNALING_VIA_NFKB" gene set. The outcome of this gene set test was plotted using the limma barcodeplot function. The EnhancedVolcano package (Blighe, Rana and Lewis, 2018) was used to produce the volcano plot. After normalization, reads were displayed as fragments per kilobase of exon per million reads (FPKM). The accession numbers for the data reported in this paper are ArrayExpress: E-MTAB-14348.

Immunoblotting and immunoprecipitation

3×10^7 total thymocytes were used per condition. For complex 1 immunoprecipitations (IPs), cells were stimulated with 2 mg/ml 3xFLAG-TNF. Cells were washed two times in ice-cold PBS before lysis in 1 ml of NP-40 lysis buffer (10% glycerol, 1% NP-40, 150 mM NaCl, and 10 mM Tris-HCl [pH 8] supplemented with phosphatase and protease inhibitor cocktail tablets [Roche Diagnostics]). The cell lysates were cleared by centrifugation for 15 min at 4 °C, and the supernatant was then incubated overnight with Anti-FLAG M2 affinity gel (Sigma Aldrich) at 4 °C. The next day, the beads were washed three times in PBS buffer. The beads were then resuspended in 10 µl Laemmli buffer to elute the immune complexes.

Linear M1-ubiquitin containing complexes were enriched using Halo tagged NEMO protein (MRC PPU Reagents and Services facility, University of Dundee), coupled to HaloLink Resin (Promega) overnight at 4 °C, according to the manufacturer's instructions. 3×10^7 total thymocytes were stimulated with 400 ng/ml human TNF (Peptotec). Cells were washed two times in ice-cold PBS before lysis in 1 ml of Triton X-100 lysis buffer (10% glycerol, 1% Triton X-100, 150 mM NaCl, and 50 mM Tris-HCl [pH 7.5], 2 mM EDTA, 10 mM N-ethylmaleimide supplemented with phosphatase and protease inhibitor cocktail tablets [Roche Diagnostics]). The cell lysates were cleared by centrifugation for 15 min at 4 °C, and the supernatant was then incubated overnight with Halo-NEMO beads at 4 °C. The next day, the beads were washed three times in Triton X-100 lysis buffer containing 0.5 M NaCl followed by one wash with 50 mM NaCl, 50 mM Tris-HCl [pH 7.5] and 2 mM DTT. The beads were then resuspended in 20 µl LDS buffer to elute the immune complexes.

IPs and total cell extracts were analysed by NuPage 4-12% Bis-Tris gel (Invitrogen Novex), transferred onto nitrocellulose membrane (Invitrogen) and immunoblotted with anti-RIPK1 (Cell Signalling Technology). Immunodetection was performed by incubation with horseradish peroxidase-conjugated anti-rabbit (1:5000) (DAKO) and developed by enhanced chemiluminescence (ThermoFisher Scientific).

Statistics

Statistical analysis, line fitting, regression analysis, and figure preparation were performed using Graphpad Prism 9. Column data compared by unpaired Mann-Witney student's t test. * $p < 0.01$, ** $p < 0.001$. Error bars show standard error of mean throughout unless otherwise stated.

DATA AVAILABILITY

"RNA-seq of NP peptide stimulated F5 huCD2iCre Ikk2fx/fx CD8 + T cells" has been assigned ArrayExpress accession E-MTAB-14348.

REFERENCES

- Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. *Trends Immunol.* 2004;25:280–8.
- Gerondakis S, Siebenlist U. Roles of the NF-kappaB pathway in lymphocyte development and function. *Cold Spring Harb Perspect Biol.* 2010;2:a000182.
- Xing Y, Wang X, Jameson SC, Hogquist KA. Late stages of T cell maturation in the thymus involve NF-κB and tonic type I interferon signaling. *Nat Immunol.* 2016;17:565–73.
- Webb LV, Barbarulo A, Huysentruyt J, Vanden Berghe T, Takahashi N, Ley S, et al. Survival of single positive thymocytes depends upon developmental control of RIPK1 kinase signaling by the IKK complex independent of NF-κB. *Immunity.* 2019;50:348–61.e344.
- Zheng Y, Vig M, Lyons J, Van Parijs L, Beg AA. Combined deficiency of p50 and cRel in CD4+ T cells reveals an essential requirement for nuclear factor kappaB in regulating mature T cell survival and in vivo function. *J Exp Med.* 2003;197:861–74.
- Ruland J, Duncan GS, Elia A, del Barco Barrantes I, Nguyen L, Plyte S, et al. Bcl10 is a positive regulator of antigen receptor-induced activation of NF-kappaB and neural tube closure. *Cell.* 2001;104:33–42.
- Egawa T, Albrecht B, Favier B, Sunshine MJ, Mirchandani K, O'Brien W, et al. Requirement for CARMA1 in antigen receptor-induced NF-kappa B activation and lymphocyte proliferation. *Curr Biol.* 2003;13:1252–8.
- Hara H, Wada T, Bakal C, Koziaradzki I, Suzuki S, Suzuki N, et al. The MAGUK family protein CARD11 is essential for lymphocyte activation. *Immunity.* 2003;18:763–75.
- Ruefli-Brasse AA, French DM, Dixit VM. Regulation of NF-kappaB-dependent lymphocyte activation and development by paracaspase. *Science.* 2003;302:1581–4.
- Ruland J, Duncan GS, Wakeham A, Mak TW. Differential requirement for Malt1 in T and B cell antigen receptor signaling. *Immunity.* 2003;19:749–58.
- Jost PJ, Weiss S, Ferch U, Gross O, Mak TW, Peschel C, et al. Bcl10/Malt1 signaling is essential for TCR-induced NF-kappaB activation in thymocytes but dispensable for positive or negative selection. *J Immunol.* 2007;178:953–60.
- Grumont R, Lock P, Mollinari M, Shannon FM, Moore A, Gerondakis S. The Mitogen-Induced Increase in T Cell Size Involves PKC and NFAT Activation of Rel/NF-κB-Dependent c-myc Expression. *Immunity.* 2004;21:19–30.
- Hayden MS, Ghosh S. NF-kappaB in immunobiology. *Cell Res.* 2011;21:223–44.
- Schmidt-Supprian M, Courtois G, Tian J, Coyle AJ, Israel A, Rajewsky K, et al. Mature T cells depend on signaling through the IKK complex. *Immunity.* 2003;19:377–89.
- Chen X, Willette-Brown J, Wu X, Hu Y, Howard OM, Hu Y, et al. IKKalpha is required for the homeostasis of regulatory T cells and for the expansion of both regulatory and effector CD4 T cells. *FASEB J.* 2015;29:443–54.
- Giordano M, Roncagalli R, Bourdely P, Chasson L, Buferne M, Yamasaki S, et al. The tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20) imposes a brake on antitumor activity of CD8 T cells. *Proc Natl Acad Sci.* 2014;111:11115–20.
- Fischer JC, Otten V, Kober M, Drees C, Rosenbaum M, Schmickl M, et al. A20 restrains thymic regulatory T cell development. *J Immunol.* 2017;199:2356–65.
- Onizawa M, Oshima S, Schulze-Topphoff U, Oses-Prieto JA, Lu T, Tavares R, et al. The ubiquitin-modifying enzyme A20 restricts ubiquitination of the kinase RIPK3 and protects cells from necroptosis. *Nat Immunol.* 2015;16:618–27.
- Duwel M, Welteke V, Oeckinghaus A, Baens M, Kloos B, Ferch U, et al. A20 negatively regulates T cell receptor signaling to NF-kappaB by cleaving Malt1 ubiquitin chains. *J Immunol.* 2009;182:7718–28.
- Yin H, Karayel O, Chao YY, Seeholzer T, Hamp I, Plettenburg O, et al. A20 and ABIN-1 cooperate in balancing CBM complex-triggered NF-kappaB signaling in activated T cells. *Cell Mol Life Sci.* 2022;79:112.
- Skaug B, Chen J, Du F, He J, Ma A, Chen ZJ. Direct, noncatalytic mechanism of IKK inhibition by A20. *Mol Cell.* 2011;44:559–71.
- Verhelst K, Carpentier I, Kreike M, Meloni L, Verstrepen L, Kensche T, et al. A20 inhibits LUBAC-mediated NF-kappaB activation by binding linear polyubiquitin chains via its zinc finger 7. *EMBO J.* 2012;31:3845–55.
- Draber P, Kupka S, Reichert M, Draberova H, Lafont E, de Miguel D, et al. LUBAC-recruited CYLD and A20 regulate gene activation and cell death by exerting opposing effects on linear ubiquitin in signaling complexes. *Cell Rep.* 2015;13:2258–72.
- Sriskantharajah S, Belich MP, Papoutsopoulos S, Janzen J, Tybulewicz V, Seddon B, et al. Proteolysis of NF-kappaB1 p105 is essential for T cell antigen receptor-induced proliferation. *Nat Immunol.* 2009;10:38–47.
- Kontgen F, Grumont RJ, Strasser A, Metcalf D, Li R, Tarlington D, et al. Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression. *Genes Dev.* 1995;9:1965–77.
- Liou HC, Jin Z, Tumang J, Andjelic S, Smith KA, Liou ML. c-Rel is crucial for lymphocyte proliferation but dispensable for T cell effector function. *Int Immunol.* 1999;11:361–71.

27. Saibil SD, Jones RG, Deenick EK, Liadis N, Elford AR, Vainberg MG, et al. CD4+ and CD8+ T Cell Survival Is Regulated Differentially by Protein Kinase C θ , c-Rel, and Protein Kinase B. *J Immunol*. 2007;178:2932–9.
28. Khoshnan A, Tindell C, Laux I, Bae D, Bennett B, Nel AE. The NF-kappa B cascade is important in Bcl-xL expression and for the anti-apoptotic effects of the CD28 receptor in primary human CD4+ lymphocytes. *J Immunol*. 2000;165:1743–54.
29. Mora AL, Corn RA, Stanic AK, Goenka S, Aronica M, Stanley S, et al. Antiapoptotic function of NF-kappaB in T lymphocytes is influenced by their differentiation status: roles of Fas, c-FLIP, and Bcl-xL. *Cell Death Differ*. 2003;10:1032–44.
30. Zhang N, He YW. The antiapoptotic protein Bcl-xL is dispensable for the development of effector and memory T lymphocytes. *J Immunol*. 2005;174:6967–73.
31. Webb LV, Ley SC, Seddon B. TNF activation of NF-kappaB is essential for development of single-positive thymocytes. *J Exp Med*. 2016;213:1399–407.
32. Liu HH, Xie M, Schneider MD, Chen ZJ. Essential role of TAK1 in thymocyte development and activation. *Proc Natl Acad Sci USA*. 2006;103:11677–82.
33. Wan YY, Chi H, Xie M, Schneider MD, Flavell RA. The kinase TAK1 integrates antigen and cytokine receptor signaling for T cell development, survival and function. *Nat Immunol*. 2006;7:851–8.
34. Oh H, Grinberg-Bleyer Y, Liao W, Maloney D, Wang P, Wu Z, et al. An NF-kB transcription-factor-dependent lineage-specific transcriptional program promotes regulatory T cell identity and function. *Immunity*. 2017;47:450–465.e455.
35. Schmidt-Suppran M, Tian J, Grant EP, Pasparakis M, Maehr R, Ovaa H, et al. Differential dependence of CD4+CD25+ regulatory and natural killer-like T cells on signals leading to NF-kappaB activation. *Proc Natl Acad Sci USA*. 2004;101:4566–71.
36. Vandebeele P, Declercq V, Van Herreweghe F, Vanden Berghe T. The role of the kinases RIP1 and RIP3 in TNF-induced necrosis. *Sci Signal*. 2010;3:re4.
37. Annibaldi A, Meier P. Checkpoints in TNF-induced cell death: implications in inflammation and cancer. *Trends Mol Med*. 2018;24:49–65.
38. Wang L, Du F, Wang X. TNF-alpha induces two distinct caspase-8 activation pathways. *Cell*. 2008;133:693–703.
39. Dondelinger Y, Aguilera MA, Goossens V, Dubuisson C, Grootjans S, Dejardin E, et al. RIPK3 contributes to TNFR1-mediated RIPK1 kinase-dependent apoptosis in conditions of cIAP1/2 depletion or TAK1 kinase inhibition. *Cell Death Differ*. 2013;20:1381–92.
40. Dondelinger Y, Jouan-Lanhoutet S, Divert T, Theatre E, Bertin J, Gough PJ, et al. NF-kappaB-independent role of IKKalpha/IKKbeta in preventing RIPK1 kinase-dependent apoptotic and necroptotic cell death during TNF signaling. *Mol Cell*. 2015;60:63–76.
41. Dondelinger Y, Vandebeele P, Bertrand MJ. Regulation of RIPK1's cell death function by phosphorylation. *Cell Cycle*. 2016;15:5–6.
42. Ting AT, Bertrand MJM. More to Life than NF-kappaB in TNFR1 Signaling. *Trends Immunol*. 2016;37:535–45.
43. Priem D, Devos M, Druwe S, Martens A, Slowicka K, Ting AT, et al. A20 protects cells from TNF-induced apoptosis through linear ubiquitin-dependent and -independent mechanisms. *Cell Death Dis*. 2019;10:692.
44. Mamalaki C, Elliott J, Norton T, Yannoutsos N, Townsend AR, Chandler P, et al. Positive and negative selection in transgenic mice expressing a T-cell receptor specific for influenza nucleoprotein and endogenous superantigen. *Dev Immunol*. 1993;3:159–74.
45. Silva A, Cornish G, Ley SC, Seddon B. NF-kappaB signaling mediates homeostatic maturation of new T cells. *Proc Natl Acad Sci USA*. 2014;111:E846–855.
46. Koenen P, Heinzel S, Carrington EM, Hoppo L, Alexander WS, Zhang JG, et al. Mutually exclusive regulation of T cell survival by IL-7R and antigen receptor-induced signals. *Nat Commun*. 2013;4:1735.
47. Degterev A, Hitomi J, Germesheid M, Ch'en IL, Korkina O, Teng X, et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. *Nat Chem Biol*. 2008;4:313–21.
48. Blanchett S, Dondelinger Y, Barbarulo A, Bertrand MJM, Seddon B. Phosphorylation of RIPK1 serine 25 mediates IKK dependent control of extrinsic cell death in T cells. *Front Immunol*. 2022;13:1067164.
49. Carty F, Layzell S, Barbarulo A, Webb L, Seddon B. Tonic IKK signalling regulates naive T cell survival in vivo by both repressing RIPK1 dependent extrinsic cell death pathways and independent activation of NFkB. *bioRxiv* 2022.
50. Emmerich CH, Ordureau A, Strickson S, Arthur JS, Pedrioli PG, Komander D, et al. Activation of the canonical IKK complex by K63/M1-linked hybrid ubiquitin chains. *Proc Natl Acad Sci USA*. 2013;110:15247–52.
51. Coornaert B, Baens M, Heynink K, Bekaert T, Haegman M, Staal J, et al. T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20. *Nat Immunol*. 2008;9:263–71.
52. Osborn SL, Diehl G, Han SJ, Xue L, Kurd N, Hsieh K, et al. Fas-associated death domain (FADD) is a negative regulator of T-cell receptor-mediated necroptosis. *Proc Natl Acad Sci USA*. 2010;107:13034–9.
53. Ch'en IL, Tsau JS, Molkenin JD, Komatsu M, Hedrick SM. Mechanisms of necroptosis in T cells. *J Exp Med*. 2011;208:633–41.
54. Ch'en IL, Beisner DR, Degterev A, Lynch C, Yuan J, Hoffmann A, et al. Antigen-mediated T cell expansion regulated by parallel pathways of death. *Proc Natl Acad Sci USA*. 2008;105:17463–8.
55. Schenk RL, Tuzlak S, Carrington EM, Zhan Y, Heinzel S, Teh CE, et al. Characterisation of mice lacking all functional isoforms of the pro-survival BCL-2 family member A1 reveals minor defects in the haematopoietic compartment. *Cell Death Differ*. 2017;24:534–45.
56. Just S, Nishanth G, Buchbinder JH, Wang X, Naumann M, Lavrik I, et al. A20 Curtails Primary but Augments Secondary CD8(+) T Cell Responses in Intracellular Bacterial Infection. *Sci Rep*. 2016;6:39796.
57. Li ZW, Omori SA, Labuda T, Karin M, Rickert RC. IKK beta is required for peripheral B cell survival and proliferation. *J Immunol*. 2003;170:4630–7.
58. Gareus R, Huth M, Breiden B, Nenci A, Rosch N, Haase I, et al. Normal epidermal differentiation but impaired skin-barrier formation upon keratinocyte-restricted IKK1 ablation. *Nat Cell Biol*. 2007;9:461–9.
59. Vereecke L, Sze M, Mc Guire C, Rogiers B, Chu Y, Schmidt-Suppran M, et al. Enterocyte-specific A20 deficiency sensitizes to tumor necrosis factor-induced toxicity and experimental colitis. *J Exp Med*. 2010;207:1513–23.
60. de Boer J, Williams A, Skavdis G, Harker N, Coles M, Tolaini M, et al. Transgenic mice with hematopoietic and lymphoid specific expression of Cre. *Eur J Immunol*. 2003;33:314–25.
61. Newton K, Dugger DL, Wickliffe KE, Kapoor N, de Almagro MC, Vucic D, et al. Activity of protein kinase RIPK3 determines whether cells die by necroptosis or apoptosis. *Science*. 2014;343:1357–60.
62. Filby A, Seddon B, Kleczkowska J, Salmund R, Tomlinson P, Smida M, et al. Fyn regulates the duration of TCR engagement needed for commitment to effector function. *J Immunol*. 2007;179:4635–44.

ACKNOWLEDGEMENTS

We thank UCL Comparative Biology Unit staff for assistance with mouse breeding and maintenance. We thank the following for generously sharing of their mouse strains: Prof Manolis Pasparakis for *Chuk* conditional strain, Prof Michael Karin for *Ikbbk* conditional strain, Prof Vishva Dixit for the RIPK1^{D138N} strain, Prof Albert Baldwin for *Rela* conditional strain and Prof Silvia Spori for providing the conditional *Tnfr1* strain. The authors declare no competing financial interests.

AUTHOR CONTRIBUTIONS

Scott Layzell - designed and performed experiments, wrote manuscript Alessandro Barbarulo - designed and performed experiments Geert van Loo - provided reagents Rudi Beyaert - provided reagents, advised on manuscript Benedict Seddon - designed experiments, wrote manuscript

FUNDING

The work in the Seddon lab is supported by the Medical Research Council UK under programme codes MR/P011225/1.

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41418-024-01383-6>.

Correspondence and requests for materials should be addressed to Benedict Seddon.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024, corrected publication 2024